12,372 trials
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24 — 0.142; -0.029 Liters (L) — p=<0.001
Chronic Kidney Disease · Chronic Renal Failure
Primary: Mean Weekly Hemoglobin Level From Week 21 to Week 24 — 10.17; 10.28 g/dL
Intra-abdominal Infection · Complicated Intra-abdominal Infection
Primary: Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Test of Cure (TOC) — 92.0; 8.0; 0.0 Percentage of Participants
Nonmetastatic Castration-Resistant Prostate Cancer · Prostate Cancer · Cancer of the Prostate
Primary: Metastasis Free Survival (MFS) — 36.6; 14.7 months — p=<0.0001
Influenza, Human
Primary: Percentage of Participants With Adverse Events — 40.0; 47.3; 25.7; 29.1 percentage of participants
Atrophy of Vagina · Menopause · Dyspareunia (Female)
Primary: Most Bothersome Symptom (MBS) Severity — -1.2; -1.0; -0.2; -1.4 units on a scale — p=0.25
Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability
Asthma
Primary: Asthma Exacerbations — 0.37; 0.48 exacerbations per year
Skin Structures and Soft Tissue Infections
Primary: Percent of Participants With ≥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline — 78.3; 76.7 percentage of participants
Idiopathic Parkinson's Disease
Primary: Pulmonary Safety Assessed by Forced Expiratory Volume in 1 Second [FEV1] — 2.778; 2.767 Liters
Migraine
Primary: Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period — -1.83; -3.23; -3.67 migraine days / month — p=< 0.001
Hereditary Inclusion Body Myopathy · Distal Myopathy With Rimmed Vacuoles · Distal Myopathy, Nonaka Type
Primary: Change From Baseline in UEC Score (Total Force in kg) at Week 48 — -2.25; -2.99 kg — p=0.5387
Chronic Sinusitis · Nasal Polyposis
Primary: Nasal Obstruction/Congestion Score — 2.36; 2.35; 1.56; 1.79 units on a scale — p=0.0074
Lymphoma
Primary: Median Progression-free Survival — NA; NA months — p=0.690
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2) — -1.32; -0.37 percentage of glycosylated haemoglobin — p=<0.001